© 2003 by Oxford University Press
Journal of the National Cancer Institute Monographs, No. 31, 3-13,2003
© 2003 Oxford University Press
ARTICLE |
Chapter 1: Human Papillomavirus and Cervical Cancer—Burden and Assessment of Causality
Affiliation: Epidemiology and Cancer Registration Unit, Catalan Institute of Oncology, Avda. Gran Via, s/n Km 2,7, 08907 L’Hospitalet de Llobregat, Barcelona, Spain.
Correspondence to: F. Xavier Bosch, M.D., Epidemiology and Cancer Registration Unit, Catalan Institute of Oncology, Avda. Gran Via, s/n Km 2,7, 08907 L’Hospitalet de Llobregat, Barcelona, Spain (e-mail: x.bosch{at}ico.scs.es).
Cervical cancer remains the second most common cancer in women worldwide and the most frequent in developing countries. Pre-neoplasic cervical lesions represent an additional burden in countries where screening is widespread. The human papillomavirus (HPV) prevalence and type distribution in normal smears and in cancer specimens are being described and show relatively small international variation. State-of-the-art detection techniques have unequivocally shown that HPV-DNA can be detected in 95% to 100% of adequate specimens of cervical cancer, supporting the claim that HPV is the necessary cause. The odds ratios for cervical cancer related to a cross sectional detection of HPV-DNA range from 50 to several hundred in all studies. The risk for any of 15 high-risk types is not statistically different from the risk reported for HPV16. The estimates of the attributable fraction range from 90% to 98%. Additional work should be done in providing information on incidence of cervical cancer and on HPV infection in areas where the disease is common. Theoretical work including modeling of the incidence could be of potential use in the evaluation of the existing and novel preventive strategies. Research is currently being conducted on the mechanisms of HPV carcinogenesis. These include the determinants of the systemic and cellular immune response to the viral infection, the interaction between the host and the virus and the relevance of the different strains and variants of the HPV viral types. Technology developments in this area suitable for epidemiological studies are needed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. F. Dempsey, A. Gebremariam, L. Koutsky, and L. Manhart Behavior in Early Adolescence and Risk of Human Papillomavirus Infection as a Young Adult: Results From a Population-Based Study Pediatrics, July 1, 2008; 122(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Woodhall, T Ramsey, C Cai, S Crouch, M Jit, Y Birks, W J Edmunds, R Newton, and C J N Lacey Estimation of the impact of genital warts on health-related quality of life Sex. Transm. Inf., June 1, 2008; 84(3): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lembo, M. Donalisio, M. Rusnati, A. Bugatti, M. Cornaglia, P. Cappello, M. Giovarelli, P. Oreste, and S. Landolfo Sulfated K5 Escherichia coli Polysaccharide Derivatives as Wide-Range Inhibitors of Genital Types of Human Papillomavirus Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1374 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Rizk, N. D. Christensen, K. M. Michael, M. Muller, P. Sehr, T. Waterboer, and M. Pawlita Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types J. Gen. Virol., January 1, 2008; 89(1): 117 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Kenter, M. J.P. Welters, A.R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al. Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity Clin. Cancer Res., January 1, 2008; 14(1): 169 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Chaturvedi, E. A. Engels, E. S. Gilbert, B. E. Chen, H. Storm, C. F. Lynch, P. Hall, F. Langmark, E. Pukkala, M. Kaijser, et al. Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk J Natl Cancer Inst, November 7, 2007; 99(21): 1634 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arbyn, A. O. Raifu, P. Autier, and J. Ferlay Burden of cervical cancer in Europe: estimates for 2004 Ann. Onc., October 1, 2007; 18(10): 1708 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Coutant, E Barranger, A Cortez, D Dabit, S Uzan, J. Bernaudin, and E Darai Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer Ann. Onc., September 1, 2007; 18(9): 1513 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Garland, M. Hernandez-Avila, C. M. Wheeler, G. Perez, D. M. Harper, S. Leodolter, G. W.K. Tang, D. G. Ferris, M. Steben, J. Bryan, et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases N. Engl. J. Med., May 10, 2007; 356(19): 1928 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D'Souza, A. R. Kreimer, R. Viscidi, M. Pawlita, C. Fakhry, W. M. Koch, W. H. Westra, and M. L. Gillison Case-Control Study of Human Papillomavirus and Oropharyngeal Cancer N. Engl. J. Med., May 10, 2007; 356(19): 1944 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ryding, L. Dahlberg, M. Wallen-Ohman, and J. Dillner Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles J. Gen. Virol., March 1, 2007; 88(3): 792 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Dunne, E. R. Unger, M. Sternberg, G. McQuillan, D. C. Swan, S. S. Patel, and L. E. Markowitz Prevalence of HPV Infection Among Females in the United States JAMA, February 28, 2007; 297(8): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.C.R. Ragin, F. Modugno, and S.M. Gollin The Epidemiology and Risk Factors of Head and Neck Cancer: a Focus on Human Papillomavirus J. Dent. Res., February 1, 2007; 86(2): 104 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Piersma, E. S. Jordanova, M. I.E. van Poelgeest, K. M.C. Kwappenberg, J. M. van der Hulst, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, G. J. Fleuren, R. Offringa, et al. High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer Cancer Res., January 1, 2007; 67(1): 354 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Giovannelli, M. C. Migliore, G. Capra, M. P. Caleca, C. Bellavia, A. Perino, E. Viviano, D. Matranga, and P. Ammatuna Penile, Urethral, and Seminal Sampling for Diagnosis of Human Papillomavirus Infection in Men J. Clin. Microbiol., January 1, 2007; 45(1): 248 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Lipke An Armamentarium of Wart Treatments Clin. Med. Res., December 1, 2006; 4(4): 273 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Block, T. Nolan, C. Sattler, E. Barr, K. E.D. Giacoletti, C. D. Marchant, X. Castellsague, S. A. Rusche, S. Lukac, J. T. Bryan, et al. Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women Pediatrics, November 1, 2006; 118(5): 2135 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Weaver Epidemiology and Natural History of Genital Human Papillomavirus Infection J Am Osteopath Assoc, March 1, 2006; 106(suppl_1): S2 - S8. [Abstract] [Full Text] [PDF]
|
|